tbuckley/cabot-search huggingface dataset:
A multicenter retrospective study on clinical features and outcome in elderly patients with hepatocellular carcinoma.
Authors: O. N. Kozyreva, D. Chi, K. P. Theall, A. X. Zhu
Journal: Journal of Clinical Oncology (2010)

e14569 Background: Age is a known risk factor for hepatocellular carcinoma (HCC), and the incidence of elderly HCC patients (pts) is increasing. However, there is a paucity of information on the clinical presentation and outcome in the elderly HCC pts. Weperformed a multicenter retrospective comparative study toassess the impact of age on potential differences in clinical characteristics, treatment patterns and outcome in HCC pts. Methods: We retrospectively analyzed HCC pts treated at two U.S. tertiary institutions from 1998 to 2008. The demographics, tumor and cirrhosis parameters, treatment, survival outcome were collected. Overall survival (OS) and HCC specific survival (HCCSS) were calculated according to Kaplan-Meier. Transplanted pts were excluded from survival analysis. Cox's regression model was used for multivariate survival analysis. Results: 335 HCC pts were included and divided into two groups: elderly (95 pts, age > 70 years) and younger (240 pts, aged < 70). Differences were seen with younger vs. elderly in the following: the M:F sex ratio of 5.8:1 vs. 1.7:1 (p < 0.0001); Diagnosis due to screening in 61.3% vs. 32.6 % (p < 0.0001); HCV positivity rate of 48.3% vs. 21.1% (p < 0.0001); Child B/C cirrhosis of 35.8% vs. 25.3% (p = 0.063). No significant age differences were seen in the following parameters: race; tumor features including staging, tumor numbers, portal vein thrombosis, AFP; CLIP; DM, BMI; treatment received including liver resection, RFA, TACE, or chemotherapy. Compared with younger, elderly received transplant less frequently (19.6% vs. 5.3%, p = 0.0002), and more likely to receive supportive care only (22.9% vs. 36.8%, p = 0.010). No differences were found in OS (p = 0.47) and HCCSS (p = 0.38) in ounger vs. Eldeerly groups. Conclusions: HCC is a life-limiting disease in elderly pts. Characteristics of elderly HCC pts included lower M:F ratio, lower HCV rate and less advanced underlying cirrhosis. Elderly pts received only supportive care more often. There is no significant difference in HCCSS by age. Prospective trials should include HCC pts without age discrimination. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bayer, Genentech
Incidence of adnexal and lymph node metastases in endometrial stromal sarcoma
Authors: L. dos Santos, K. Garg, J. P. Diaz, R. A. Soslow, M. L. Hensley, K. M. Alektiar, R. R. Barakat, M. M. Leitao
Journal: Journal of Clinical Oncology (2009)

5589 Background: To determine the incidence of adnexal and lymph node (LN) metastases in endometrial stromal sarcoma (ESS). Methods: We identified all cases evaluated at our institution with a diagnosis of ESS from January 1, 1980 to December 31, 2007. All uterine pathology was reviewed at our center. High-grade or undifferentiated tumors and ESS arising in extrauterine sites were excluded. Pertinent clinical data were abstracted from electronic medical records. Appropriate statistical tests were performed using SPSS 15.0. Results: We identified 91 cases with ESS. All except two underwent hysterectomy. Eighty-four cases (92%) underwent salpingo-oophorectomy (bilateral in 81 [96%]). Adnexal metastases were identified in 8 (9.5%) of 84 cases. All adnexal metastases were manifested by gross adnexal tumor and occurred in patients with other gross pelvic extrauterine disease. Seven of these 8 patients also had lymph-vascular space invasion (LVSI). LVSI status was not reported in the other patient. In patients with gross pelvic extrauterine disease, adnexal metastasis did not affect survival. LN metastases were identified in 8 (24%) of the 34 patients who underwent LN evaluation. Thirty-three evaluations were performed intraoperatively and one was via postoperative CT-guided biopsy of an enlarged LN. Five of the 8 cases with LN metastases had LVSI. LVSI status was not reported in the other 3 cases. Of 20 patients with disease grossly limited to the uterus and grossly normal LN, 2 (10%) had LN metastases. Both of these cases had LVSI and extensive myoinvasion approaching the serosa. Four of the remaining 6 patients with LN metastases had grossly positive LN and other gross extrauterine disease. The final 2 patients had grossly positive LN without other extrauterine disease. Conclusions: The incidence of LN metastases in ESS is most commonly associated with gross extrauterine disease, extensive myoinvasion and LVSI. However, since myoinvasion and LVSI status often are not assessable at the time of initial hysterectomy, LN dissection remains a reasonable option at primary surgery. The rate of adnexal metastasis appears to be negligible in the absence of gross adnexal and extrauterine tumor, but there may be a role for oophorectomy in the hormonal management of ESS. No significant financial relationships to disclose.
Phase I trial of weekly paclitaxel in 5-FU failure metastatic gastric cancer with pharmacogenomic analysis
Authors: K. Yoshida, T. Tetsuya, A. Takagane, K. Saito, A. Tsuburaya, O. Kobayashi, W. Yamamoto, M. Matsukawa, H. Kuwano, M. Nishiyama
Journal: Journal of Clinical Oncology (2004)

4224 Background: 5-fluorouracil (5-FU) based chemotherapy is regarded as the front-line therapy for metastatic gastric cancer, but little is known about the second-line regimen, including 5-FU pre-treated cases, and the perosonalization is an intensitive subject as the future treatment strategy. Methods: We conducted a phase I trial of weekly TXL in 5-FU failure advanced gastric cancer patients with typical eligibility criteria, and simultaneously performed the pharmacogenomic analysis. TXL was given by 1-hour iv infusion on days 1, 8, and 22 at escalating doses (60, 70, 80, 90,depends on document reviewand 100 mg/m2) followed by a week interval. Results: A total of 21 patients were entered into this study. All the cases were assessable for safety. Grade 4 neutropenia was observed only in one patient at level 2 and dose-dependent myelosuppresion was not seen. The study did not reach the maximum tolerated dose, but 2 patients died at level 5 (100 mg/m2): 1 due to toxicity accompanied with grade 3 motor neurolopathy (DLT) and 1 due to cancer progression with prolonged hematologic toxicities. TXL showed a non-linear pharmacokinetic pattem and satisfactory AUC was obtained from level 3 (80 mg/m2). One complete response, 3 partial responses, and 9 stable deseases were seen (the median survival: 259 days). As for genotype analysis, novel point mutation of CYP2C8 promoter region was found in 4 of the 21 patients and CYP3A4*16 was detected in 1, which possibly was related to grade 3 and 4 toxicities. Conclusions: Weekly paclitaxel therapy (level 4: 90 mg/m2) is well-tolerated and probably active in 5-FU failure advanced gastric cancer patients. Phase II trial is planned based on the antitumor activity, tolerability, and pharamacogenomic patterns observed in this study. No significant financial relationships to disclose.
Unusual Manifestations of Acute Leukemia
Authors: Meir Wetzler, Nora Lincoff
Journal: Journal of Clinical Oncology (2000)

Article Tools Unusual Manifestations of Acute Leukemia Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.19.3439 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11013286 Unusual Manifestations of Acute Leukemia Meir WetzlerxMeir WetzlerSearch for articles by this author , Nora LincoffxNora LincoffSearch for articles by this author Show More Roswell Park Cancer Institute and Buffalo General Hospital, Buffalo, NY https://doi.org/10.1200/JCO.2000.18.19.3439 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Identification and Misidentification of the Chromosomes of Heteroploid Cell Lines
Authors: J. R. Walker
Journal: JNCI Journal of the National Cancer Institute (1973)

The comparison of banded and unbanded karyotypes prepared from single cells of the HeLa line permitted a quantitative estimate of the errors involved in karyotyping transformed cell lines. A series of banded cells was analyzed to provide data on the stability of the chromosome groups and to determine the derivation of several marker chromosomes.
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
Authors: S L Berg, S M Blaney, P C Adamson, M O'Brien, D G Poplack, C Arndt, J Blatt, F M Balis
Journal: Journal of Clinical Oncology (1998)

PURPOSE To define the maximum-tolerated dose (MTD), quantitative and qualitative toxicities, recommended phase II dose, and pharmacokinetics of pyrazoloacridine (PZA) administered as a 1- or 24-hour infusion in children and young adults with refractory cancers. PATIENTS AND METHODS Twenty-two patients received PZA as a 1-hour infusion at doses of 380 mg/m2 (n = 3), 495 mg/m2 (n = 6), 640 mg/m2 (n = 6), and 835 mg/m2 (n = 7). An additional four patients received PZA as a 24-hour infusion at the MTD (640 mg/m2) for the 1-hour infusion schedule. Plasma samples were obtained for pharmacokinetic analysis in 17 patients. PZA concentration in plasma was measured by reverse-phase high-performance liquid chromatography (HPLC). A two-compartment pharmacokinetic model was fit to the PZA plasma concentration data. RESULTS On the 1-hour infusion schedule, dose-limiting myelosuppression (neutropenia more than thrombocytopenia) was observed in two of seven patients at the 835-mg/m2 dose level. Myelosuppression did not appear to be ameliorated by prolonging the infusion to 24 hours. Nonhematologic toxicities were minor. Significant neurotoxicity, which was dose-limiting in adults treated with a 1-hour infusion of PZA, was observed in one patient treated at 640 mg/m2, but was not dose-limiting. There was marked interpatient variability in plasma PZA concentrations at all dose levels. The pharmacokinetic profile of PZA was characterized by an initial rapid decline (alpha half-life [t(1/2)alpha], 0.5 hours) followed by a prolonged elimination phase (t(1/2)beta, 30 hours). The volume of distribution at steady-state (Vd(ss)) was 700 L/m2 and the clearance was 300 mL/min/m2. There was no evidence of dose-dependent clearance. The area under the PZA concentration-time curve (AUC) correlated poorly with dose and was more predictive of the degree of myelosuppression than was PZA dose. CONCLUSION PZA administered as 1- or 24-hour infusion is well tolerated by children and young adults. The dose-limiting toxicity (DLT) is myelosuppression. Neurotoxicity is not prominent in this age group. There was marked interpatient variation in plasma concentrations of PZA. The recommended dose for phase II studies is 640 mg/m2.
One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.
Authors: S E Rivkin, S Green, B Metch, W R Jewell, J J Costanzi, S J Altman, J P Minton, R M O'Bryan, C K Osborne
Journal: Journal of Clinical Oncology (1993)

PURPOSE To determine if prolonged adjuvant treatment (2 years v 1 year) with combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil [5-FU], vincristine, and prednisone [CMFVP]) in poor-prognosis breast cancer patients (estrogen receptor [ER]-negative, stage II to IIIA) would result in improved disease-free and overall survival rates. PATIENTS AND METHODS Four hundred forty-five women with ER-negative node-positive breast cancer were enrolled by the Southwest Oncology Group (SWOG) over a period of 5 years (1979 to 1984). Randomized assignments were made to either 1 or 2 years of adjuvant CMFVP. Doses were daily oral cyclophosphamide 60 mg/m2, intravenous (i.v.) weekly methotrexate 15 mg/m2, i.v. weekly 5-FU 400 mg/m2, i.v. weekly vincristine .625 mg/m2 for the first 10 weeks, and prednisone weeks 1 through 6 with doses decreasing from 30 mg/m2 to 10 mg/m2. RESULTS The median follow-up duration is 8.6 years, with a maximum of 11.3 years. Treatment arms were not significantly different as regards either survival or disease-free survival rates (P = .33 and P = .24, respectively). The five-year survival rate is 57% on the 1-year arm and 62% on the 2-year arm. Patients with three or fewer nodes and premenopausal status were associated with improved survival. Compliance on the 2-year arm was poor, with only 37% completing the full 2 years of treatment. SWOG grade 3 to 4 toxicity was experienced by 47% of patients on the 1-year arm and by 52% on the 2-year arm. There were no treatment-related deaths. CONCLUSION We conclude that 2-year adjuvant treatment with CMFVP is not an improvement over 1-year treatment. Moreover, 2 years of CMFVP is difficult to complete. However, the results are not definitely negative. A moderate improvement attributed to prolonged chemotherapy, especially among patients with four or more positive nodes, cannot be ruled out.
Long-lasting responses after four doses of rituximab in Waldenström's macroglobulinemia: Clinical value of minor responses: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial
Authors: M. A. Gertz, R. Abonour, L. T. Heffner, P. R. Greipp, H. Uno, S. V. Rajkumar
Journal: Journal of Clinical Oncology (2009)

8513 Background: Waldenström's macroglobulinemia is a low-grade lymphoplasmacytic lymphoma that is responsive to rituximab. Uniform response criteria define an objective response as a 50% reduction in the IgM level, and a minor response as a 25% reduction in IgM level. No publications in the literature exist that justify the use of the minor response. Clinicians who treat patients that achieve a minor response are left uncertain as to whether the response is adequate and patients should be monitored for progression or whether they should be considered therapy failures and crossover to an alternate chemotherapy regimen in an effort to achieve a deeper response. Methods: 69 patients, 34 previously untreated, and 35 previously treated (but rituximab naive) were included. All patients were treated with a single four-week course of rituximab 375 mg/m 2 and were monitored with no further therapy until progression. Results: There were 19 objective and 17 minor responses out of 69 eligible patients (52.2%). Response rate and progression-free survival (26.6 mo) were similar whether patients were previously untreated or previously treated. Previously treated rituximab-naïve and previously untreated patients had, five-year survivals of 48% and 85%, respectively. There was no difference in overall or progression free survival between patients who achieved an objective response when compared to those who achieved a minor response. There was no difference between objective and minor responders by age, time from diagnosis to treatment in the treated group, bone marrow lymphoplasmacytes, hemoglobin level, creatinine, IgM level, or M-spike. The pre-treatment level of IgM did not predict overall survival, progression-free survival, time to progression, or response rate (All p&gt;0.05). This lack of significance was found whether IgM was assessed as a continuous or discrete variable. Conclusions: These results reconfirm rituximab's efficacy as a single-agent for the treatment of Waldenström's macroglobulinemia, and patients who have a 25–50% reduction in their IgM protein derive significant clinical benefits that are durable and appear to not have an impact on overall survival. No significant financial relationships to disclose.
First line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC). A Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression free survival
Authors: G. B. Kristensen, I. Vergote, E. Eisenhauer, M. Baekelandt, G. Stuart, E. Aavall-Lundquist, J. Del Campo, A. B. Lopez, M. Mirza, E. Lorenz
Journal: Journal of Clinical Oncology (2004)

5003 Background: Adding anthracyclin to conventional platinum based chemotherapy of ovarian cancer has been found to improve survival. The aim of the present study was to evaluate the effect on survival of adding epirubicin to the standard treatment with carboplatin and paclitaxel. Methods: Between March 1999 and August 2001, 887 patients were randomized to receive 6–9 cycles of paclitaxel (175 mg/m2, 3 h iv) followed by carboplatin (AUC 5, Calvert formula) with or without epirubicin (75 mg/m2 iv prior to paclitaxel) on a 3-weekly schedule. The primary endpoint was progression-free survival and 542 progression events were required to detect a hazard ratio of 0.786 or less. Results: Patient characteristics were similar across the treatment arms. Residual disease less than 1 cm at surgery with no measurable disease before chemotherapy was reported in 328 patients (37%), with 159 in the TEC and 169 in the TC arm. A total of 63 patients had to be withdrawn from the study, 20 were ineligible, 32 due to hypersensitivity reaction to paclitaxel during the first or second course and 11 withdraw informed consent, leaving 824 patients for the survival analysis. The median follow up is 30 months for patients still alive. Progressive disease has been reported for 573 patients and 326 have died. In the total group of patients, the median time to progression was 17.2 months in the TEC arm and 16.3 in the TC arm (p=0.99) . In the group with residual tumor of 1 cm or less, the median time to progression was 24.7 months in the TEC arm and 24.4 months in the TC arm (p=0.94). In patients with more than 1 cm of residual tumor, the median time to progression in the TEC arm was 14.6 months and 13.8 months in the TC arm (p=0.75). The median overall survival has not yet been reached. Conclusions: The addition of epirubicin to the standard carboplatin and paclitaxel treatment did not improve progression free survival. The evaluation of effect on long term survival awaits further follow up. No significant financial relationships to disclose.
Risk Stratification In Chronic Lymphocytic Leukemia Patients With IGHV3-21 Gene Usage According To Presence Of Stereotypy and Mutations In SF3B1
Authors: Sabine Jeromin, Frank Dicker, Katharina Bayer, Sandra Weissmann, Christiane Eder, Manja Meggendorfer, Tamara Alpermann, Alexander Kohlmann, Torsten Haferlach, Wolfgang Kern, Claudia Haferlach, Susanne Schnittger
Journal: Blood (2013)
Late side effects of osteosarcoma neoadjuvant chemotherapy: The experience at Rizzoli institute
Authors: A. Longhi, S. Ferrari, C. Ferrari, M. Cesari, E. Palmerini, G. Bacci
Journal: Journal of Clinical Oncology (2006)

9508 Background: Good cure rate has been reached in osteosarcoma treatment with chemotherapy, but there are late side effects. Methods: We reviewed charts of 755 patients (pts) with localized osteosarcoma of the extremity treated in 6 subsequent protocols (1983–2000) with Doxorubicin (300–480 mg/m 2 ), Cisplatin (300–600 mg/m 2 ), Methotrexate (3.7–75 g/m 2 ), Ifosfamide (30–75 g/m 2 ). Etoposide was employed only in 47 pts. Results: With a median follow up of 8 yrs (5–20), the median 10-yrs EFS was 58%. 13 patients (1.7%), 9 females and 4 males, had a symptomatic cardiopathy with two cardiopathy-related deaths, and 3 patients needed a heart transplant. The median age of these pts was 13 yrs (4–28). Median Doxorubicine dose = 480 mg/m 2 . Median interval from chemotherapy completion to cardiopathy onset was 3 months; 7 patients are alive, and 6 died: 4 for cardiopathy, 2 for metastatic disease. 17 second malignant neoplasms (SMN) occurred in 16 pts (2.1%) after a median interval of 7 yrs. One patient had both a breast and ovarian cancer. SMN were: 2 AML, 3 ALL, 1 CML, 3 breast cancer, 1 CNS tumor, 1 lung tumor, 1 parotid tumor, 2 soft tissue sarcoma, 1 skin cancer, 1 ovary cancer, 1 Ewing sarcoma. Eight of these 16 pts died of the second tumor. Infertility related to chemotherapy affected mostly males. Amenorrhea affected 69% of postpubertal females during chemotherapy but only two pts had permanent amenorrhea (39 and 43 yrs). No delay in pubertal maturation was seen in both gender. The incidence of infertility in male was related to Ifosfamide and was dose-dependent. Permanent azoospermia was 100% in males who received 60–75g/m 2 Ifosfamide. No congenital defects were observed in the offsprings of both gender. The incidence of chronic renal failure was negligible in pts who received &lt;60g/m 2 Ifosfamide; in those who received &gt;60 g/m 2 a subclinical tubular impairment was observed in 48%, but only 1pt required dialysis. In the last protocol, a mild hearing impairment due to Cisplatin was evident in 40% of pts. Conclusions: Late toxicities are relevant and prolonged follow-ups are recommended as well as less toxic protocols. No significant financial relationships to disclose.
Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis
Authors: L. Koutcher, M. Fury, S. Wolden, Z. Zhang, Q. Mo, M. Zelefsky, D. Kraus, E. Sherman, D. Pfister, N. Lee
Journal: Journal of Clinical Oncology (2009)

6042 Background: Both concurrent CDDP/RT and C/RT have been shown in randomized trials to yield superior disease control compared to RT alone in LAHNC, but no randomized trial has compared them. We evaluated our center's experience with these regimens. Methods: From 3/1/06 - 4/1/08, 175 patients were retrospectively identified who received definitive treatment for LAHNC with CDDP (planned total dose 100 mg/m 2 Q3 weeks X 3) and RT (n = 125) or C (400 mg/m 2 load; 250 mg/m 2 weekly) and RT (n = 50). Patients who received prior RT, additional systemic therapy, and/or surgery to the primary site were excluded. C was given for the following reasons: auditory 30%, renal 4%, cardiac 2%, performance status 18%, patient choice 16%, neuropathy 4%, unknown 2%, and a combination of factors 24%. The median age: CDDP group 56, 6% &gt;71; C group 66.5, 40% &gt;71. Additional CDDP and C features: male sex, 86 v 78%; stage IV, 70 v 68%; and oropharynx, 78 v 70%. Median RT dose (70 Gy), RT length (46 days), and Karnofsky performance status (KPS) (90%) were the same; alcohol/tobacco use was similar. Results: At a median follow up of 18.7 months, with death without local failure (LF) as a competing risk, the 18 month LF incidence rate was 2.5% in the CDDP group and 43.3% in the C group (p &lt; 0.0001), with the latest event occurring at 16.5 months. The 18 month disease-free survival (DFS) and overall survival (OS) rates were 85.7 v 40.9%, and 96.8 v 73.1%, in favor of CDDP (p &lt; 0.0001 for both). Initially, 21 variables were assessed for significance, and when Cox proportional hazards model was used for multivariate analysis to address prognostic imbalances, treatment with CDDP still predicted for improved LF, DFS, and OS (p &lt; 0.0001 for LF and DFS; p = 0.0017 for OS). For OS analysis, the concordance probability estimates were .67 for using drug choice alone and .80 for using drug choice, T stage, RT dose, and KPS. Conclusions: CDDP/RT and C/RT were used to treat somewhat different populations with LAHNC. The observed superiority of CDDP/RT compared to C/RT in LF, DFS, and OS may reflect patient selection issues. However, preliminary multivariate modeling suggests that CDDP/RT remains the preferred option for fit patients pending further analyses and prospective studies comparing these regimens. [Table: see text]